Phaseline

Targets › FOXO1

FOXO1 (Forkhead box protein O1): drug programs, companies and trials

1 program from 1 company in 4 trials: 2 Phase 3, 1 Phase 2, 1 Phase 1; Oncology; next expected readout Mar 2027.

Transcription factor that is the main target of insulin signaling and regulates metabolic homeostasis in response to oxidative stress. Binds to the insulin response element (IRE) with consensus sequence 5'-TT[G/A]TTTTG-3' and the related Daf-16 family binding element (DBE) with consensus sequence 5'-TT[G/A]TTTAC-3'. Activity suppressed by insulin. (UniProt, Q12778)

Open in Phaseline: the race on FOXO1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Suzhou Suncadia BiopharmaceuticalsSHR-A2102 for Injection
Forkhead box protein O1 (FOXO1) inhibitor
FOXO1Phase 3Recurrent Cervical Cancer; Locally Advanced or Metastatic Urothelial Carcinoma; Muscular Invasive Bladder Cancer (MIBC); Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaMar 2027

Conditions

Recurrent Cervical Cancer (1) Locally Advanced or Metastatic Urothelial Carcinoma (1) Muscular Invasive Bladder Cancer (MIBC) (1) Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (1)

Modalities

mixed (1)

Companies

Suzhou Suncadia Biopharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.